drugset
drugset / Trial / NCT02949570

Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

NCT02949570 ↗

Phase 2 Unknown 54 enrolled Hybrigenics Corporation
NaSingle-groupOpen-labelTreatment

Summary

To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.

Timeline

Start
2014-02
Primary completion
2018-02
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Inecalcitol Small molecule — —

Indications

chronic myeloid leukemia